{ "name": "GLP-1 Briefing change archive", "description": "Every change this site has observed in the public GLP-1 drug record. ClinicalTrials.gov, Drugs@FDA and the FDA shortage database revise in place and keep no public history; these are the superseded values.", "source": "https://glp1briefing.com", "documentation": "https://glp1briefing.com/changes.html", "license": "CC BY 4.0", "license_url": "https://creativecommons.org/licenses/by/4.0/", "attribution": "GLP-1 Briefing (https://glp1briefing.com)", "generated": "2026-10-19T10:10:49+00:00", "count": 272, "count_observed_changes": 134, "count_first_sightings": 138, "fields": { "observed": "Date this site saw the change (UTC). Not the date the sponsor filed it.", "kind": "new = first time this record was seen. status, completion_moved, enrollment, field_changed = an observed change.", "source": "trials, approvals, labels or shortages. Empty on seed entries.", "drug": "INN of the molecule.", "nct_id": "ClinicalTrials.gov identifier, where the record is a trial.", "application": "FDA application number, where the record is an approval or label.", "field": "Which field changed. Empty when kind is new.", "previous": "What the field said before. Empty when this site never saw an earlier value.", "current": "What it says now.", "months": "Months the completion date moved; negative means it came forward.", "significance": "0 routine, 1 notable, 2 lead story. This site's own judgement.", "title": "Record title as filed.", "sponsor": "Sponsor as filed.", "phase": "Trial phase as filed.", "record_url": "The primary record this row was built from." }, "changes": [ { "observed": "2026-10-15", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06716216", "application": "", "field": "primary_completion_date", "previous": "2026-03-20", "current": "2026-11-14", "months": "8", "significance": "2", "title": "A Study of BGM0504 in Participants With Type 2 Diabetes", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06716216" }, { "observed": "2026-10-15", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07845500", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity", "sponsor": "Pfizer", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07845500" }, { "observed": "2026-10-15", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06716216", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Study of BGM0504 in Participants With Type 2 Diabetes", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06716216" }, { "observed": "2026-10-15", "kind": "new", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07874828", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study", "sponsor": "M.D. Anderson Cancer Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07874828" }, { "observed": "2026-10-14", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT05195944", "application": "", "field": "status", "previous": "ENROLLING_BY_INVITATION", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Semaglutide vs Sitagliptin", "sponsor": "University Health Network, Toronto", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT05195944" }, { "observed": "2026-10-14", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07872904", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "FutureShape Family", "sponsor": "Signe Torekov", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07872904" }, { "observed": "2026-10-14", "kind": "status", "source": "trials", "drug": "aleniglipron", "nct_id": "NCT07169942", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Aleniglipron Phase 2 Body Composition Study", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07169942" }, { "observed": "2026-10-14", "kind": "completion_moved", "source": "trials", "drug": "aleniglipron", "nct_id": "NCT07169942", "application": "", "field": "primary_completion_date", "previous": "2026-08", "current": "2026-09-09", "months": "1", "significance": "0", "title": "Aleniglipron Phase 2 Body Composition Study", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07169942" }, { "observed": "2026-10-13", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07064486", "application": "", "field": "primary_completion_date", "previous": "2026-07-31", "current": "2027-04-30", "months": "9", "significance": "2", "title": "A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07064486" }, { "observed": "2026-10-13", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07064486", "application": "", "field": "enrollment", "previous": "477", "current": "152", "months": "", "significance": "1", "title": "A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07064486" }, { "observed": "2026-10-13", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06639464", "application": "", "field": "primary_completion_date", "previous": "2026-08-31", "current": "2027-09-01", "months": "13", "significance": "1", "title": "Semaglutide for Helping Opioid Recovery", "sponsor": "Brigham and Women's Hospital", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06639464" }, { "observed": "2026-10-13", "kind": "status", "source": "trials", "drug": "ecnoglutide", "nct_id": "NCT07553299", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "TERMINATED", "months": "", "significance": "1", "title": "A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "sponsor": "Verdiva Bio Dev Limited", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07553299" }, { "observed": "2026-10-13", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07064486", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07064486" }, { "observed": "2026-10-13", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07871799", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging", "sponsor": "Sheba Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07871799" }, { "observed": "2026-10-13", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07870538", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum", "sponsor": "Universitaire Ziekenhuizen KU Leuven", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07870538" }, { "observed": "2026-10-13", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07547878", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "ENROLLING_BY_INVITATION", "months": "", "significance": "0", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "sponsor": "Baylor Research Institute", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "observed": "2026-10-13", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07817875", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07817875" }, { "observed": "2026-10-13", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06911203", "application": "", "field": "status", "previous": "RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "A Study of BGM0504 in Participants With Obesity", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06911203" }, { "observed": "2026-10-13", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06911203", "application": "", "field": "primary_completion_date", "previous": "2026-01-11", "current": "2026-01-14", "months": "0", "significance": "0", "title": "A Study of BGM0504 in Participants With Obesity", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06911203" }, { "observed": "2026-10-13", "kind": "enrollment", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06911203", "application": "", "field": "enrollment", "previous": "90", "current": "96", "months": "", "significance": "0", "title": "A Study of BGM0504 in Participants With Obesity", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06911203" }, { "observed": "2026-10-13", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06191848", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)", "sponsor": "University of Melbourne", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06191848" }, { "observed": "2026-10-13", "kind": "status", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07657676", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity", "sponsor": "China National Center for Cardiovascular Diseases", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07657676" }, { "observed": "2026-10-13", "kind": "completion_moved", "source": "trials", "drug": "ecnoglutide", "nct_id": "NCT07553299", "application": "", "field": "primary_completion_date", "previous": "2026-11-30", "current": "2026-09-11", "months": "-2", "significance": "0", "title": "A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "sponsor": "Verdiva Bio Dev Limited", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07553299" }, { "observed": "2026-10-13", "kind": "enrollment", "source": "trials", "drug": "ecnoglutide", "nct_id": "NCT07553299", "application": "", "field": "enrollment", "previous": "120", "current": "8", "months": "", "significance": "0", "title": "A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "sponsor": "Verdiva Bio Dev Limited", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07553299" }, { "observed": "2026-10-13", "kind": "new", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07871409", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07871409" }, { "observed": "2026-10-09", "kind": "new", "source": "trials", "drug": "VK2735", "nct_id": "NCT07868939", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)", "sponsor": "Viking Therapeutics, Inc.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07868939" }, { "observed": "2026-10-09", "kind": "new", "source": "trials", "drug": "VK2735", "nct_id": "NCT07868835", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)", "sponsor": "Viking Therapeutics, Inc.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07868835" }, { "observed": "2026-10-09", "kind": "new", "source": "approvals", "drug": "exenatide", "nct_id": "", "application": "ANDA206697", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "AMNEAL", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=A206697" }, { "observed": "2026-10-09", "kind": "new", "source": "approvals", "drug": "exenatide", "nct_id": "", "application": "ANDA206697", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "AMNEAL", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=A206697" }, { "observed": "2026-10-09", "kind": "new", "source": "approvals", "drug": "exenatide", "nct_id": "", "application": "ANDA206697", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "AMNEAL", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=A206697" }, { "observed": "2026-10-08", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07866066", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07866066" }, { "observed": "2026-10-07", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06896981", "application": "", "field": "status", "previous": "RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Semaglutide in Women With Polycystic Ovary Syndrome and Obesity", "sponsor": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", "phase": "P2/P3", "record_url": "https://clinicaltrials.gov/study/NCT06896981" }, { "observed": "2026-10-07", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06896981", "application": "", "field": "enrollment", "previous": "30", "current": "31", "months": "", "significance": "0", "title": "Semaglutide in Women With Polycystic Ovary Syndrome and Obesity", "sponsor": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", "phase": "P2/P3", "record_url": "https://clinicaltrials.gov/study/NCT06896981" }, { "observed": "2026-10-07", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT05726227", "application": "", "field": "enrollment", "previous": "210", "current": "212", "months": "", "significance": "0", "title": "A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight", "sponsor": "Novo Nordisk A/S", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT05726227" }, { "observed": "2026-10-07", "kind": "status", "source": "trials", "drug": "petrelintide", "nct_id": "NCT07843472", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease", "sponsor": "Hoffmann-La Roche", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07843472" }, { "observed": "2026-10-07", "kind": "status", "source": "trials", "drug": "petrelintide", "nct_id": "NCT07843498", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity", "sponsor": "Hoffmann-La Roche", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07843498" }, { "observed": "2026-10-07", "kind": "status", "source": "trials", "drug": "petrelintide", "nct_id": "NCT07843485", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes", "sponsor": "Hoffmann-La Roche", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07843485" }, { "observed": "2026-10-06", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07284979", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes", "sponsor": "Kailera", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07284979" }, { "observed": "2026-10-06", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07284979", "application": "", "field": "enrollment", "previous": "1200", "current": "1270", "months": "", "significance": "0", "title": "Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes", "sponsor": "Kailera", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07284979" }, { "observed": "2026-10-06", "kind": "completion_moved", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07225686", "application": "", "field": "primary_completion_date", "previous": "2027-09-03", "current": "2027-08-20", "months": "-1", "significance": "0", "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07225686" }, { "observed": "2026-10-05", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06058585", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect", "sponsor": "The George Institute", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06058585" }, { "observed": "2026-10-05", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06073184", "application": "", "field": "primary_completion_date", "previous": "2027-02", "current": "2029-02", "months": "24", "significance": "1", "title": "Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium", "sponsor": "GynOncTrials", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06073184" }, { "observed": "2026-10-05", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07859189", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07859189" }, { "observed": "2026-10-05", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07859176", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07859176" }, { "observed": "2026-10-05", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07859137", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m\u00b2 or Higher", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07859137" }, { "observed": "2026-10-05", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07859163", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07859163" }, { "observed": "2026-10-05", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07859150", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07859150" }, { "observed": "2026-10-05", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07858331", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access", "sponsor": "Kristin Clemens", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07858331" }, { "observed": "2026-10-05", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06073184", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium", "sponsor": "GynOncTrials", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06073184" }, { "observed": "2026-10-02", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06861439", "application": "", "field": "primary_completion_date", "previous": "2026-10-30", "current": "2027-10-30", "months": "12", "significance": "1", "title": "GLP-1s to Enhance Lasting Optimal Weight", "sponsor": "Wake Forest University Health Sciences", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06861439" }, { "observed": "2026-10-02", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07855900", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "SYNCHRONIZE\u00ae-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight", "sponsor": "Boehringer Ingelheim", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07855900" }, { "observed": "2026-10-02", "kind": "status", "source": "trials", "drug": "orforglipron", "nct_id": "NCT07153471", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07153471" }, { "observed": "2026-10-01", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07112872", "application": "", "field": "primary_completion_date", "previous": "2026-11-27", "current": "2028-02-05", "months": "15", "significance": "1", "title": "A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes", "sponsor": "Hoffmann-La Roche", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07112872" }, { "observed": "2026-10-01", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06184633", "application": "", "field": "primary_completion_date", "previous": "2026-05-01", "current": "2027-04-10", "months": "11", "significance": "1", "title": "DUTCH Weight Control in Atrial Fibrillation Study", "sponsor": "Rijnstate Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06184633" }, { "observed": "2026-10-01", "kind": "enrollment", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07734792", "application": "", "field": "enrollment", "previous": "430", "current": "726", "months": "", "significance": "1", "title": "Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial", "sponsor": "yifang zhu", "phase": "P2/P3", "record_url": "https://clinicaltrials.gov/study/NCT07734792" }, { "observed": "2026-10-01", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT05254314", "application": "", "field": "primary_completion_date", "previous": "2026-09-30", "current": "2026-09-28", "months": "0", "significance": "0", "title": "Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)", "sponsor": "Vanderbilt University Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT05254314" }, { "observed": "2026-10-01", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07112872", "application": "", "field": "enrollment", "previous": "240", "current": "330", "months": "", "significance": "0", "title": "A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes", "sponsor": "Hoffmann-La Roche", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07112872" }, { "observed": "2026-10-01", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06184633", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "DUTCH Weight Control in Atrial Fibrillation Study", "sponsor": "Rijnstate Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06184633" }, { "observed": "2026-10-01", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06287307", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "UNKNOWN", "months": "", "significance": "0", "title": "Semaglutide 2.4mg for Low Responders After Bariatric Surgery", "sponsor": "Zuyderland Medisch Centrum", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06287307" }, { "observed": "2026-09-30", "kind": "new", "source": "trials", "drug": "survodutide", "nct_id": "NCT07850063", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease", "sponsor": "Boehringer Ingelheim", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07850063" }, { "observed": "2026-09-30", "kind": "new", "source": "trials", "drug": "survodutide", "nct_id": "NCT07850050", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "SYNCHRONIZE\u00ae-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight", "sponsor": "Boehringer Ingelheim", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07850050" }, { "observed": "2026-09-30", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT04892199", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "UNKNOWN", "months": "", "significance": "0", "title": "Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?", "sponsor": "Anders Fink-Jensen, MD, DMSci", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT04892199" }, { "observed": "2026-09-30", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06854614", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)", "sponsor": "The Cleveland Clinic", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06854614" }, { "observed": "2026-09-30", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07817251", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema", "sponsor": "Novo Nordisk A/S", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07817251" }, { "observed": "2026-09-29", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07845500", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity", "sponsor": "Pfizer", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07845500" }, { "observed": "2026-09-29", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07845994", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years", "sponsor": "University Hospital, Angers", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07845994" }, { "observed": "2026-09-29", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06771115", "application": "", "field": "enrollment", "previous": "176", "current": "175", "months": "", "significance": "0", "title": "Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity", "sponsor": "Zomagen Biosciences Ltd.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06771115" }, { "observed": "2026-09-29", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07724340", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity", "sponsor": "Antag Therapeutics", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07724340" }, { "observed": "2026-09-29", "kind": "new", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07846865", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial", "sponsor": "Woolcock Institute of Medical Research", "phase": "P2/P3", "record_url": "https://clinicaltrials.gov/study/NCT07846865" }, { "observed": "2026-09-29", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06603571", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "sponsor": "Eli Lilly and Company", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06603571" }, { "observed": "2026-09-29", "kind": "status", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07226765", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07226765" }, { "observed": "2026-09-29", "kind": "completion_moved", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07226765", "application": "", "field": "primary_completion_date", "previous": "2027-09-29", "current": "2027-08-30", "months": "-1", "significance": "0", "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07226765" }, { "observed": "2026-09-28", "kind": "new", "source": "trials", "drug": "petrelintide", "nct_id": "NCT07843472", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease", "sponsor": "Hoffmann-La Roche", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07843472" }, { "observed": "2026-09-28", "kind": "new", "source": "trials", "drug": "petrelintide", "nct_id": "NCT07843485", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes", "sponsor": "Hoffmann-La Roche", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07843485" }, { "observed": "2026-09-28", "kind": "new", "source": "trials", "drug": "petrelintide", "nct_id": "NCT07843498", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity", "sponsor": "Hoffmann-La Roche", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07843498" }, { "observed": "2026-09-28", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07668414", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide", "sponsor": "Novo Nordisk A/S", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07668414" }, { "observed": "2026-09-28", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06260722", "application": "", "field": "primary_completion_date", "previous": "2026-08", "current": "2026-08-27", "months": "0", "significance": "0", "title": "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06260722" }, { "observed": "2026-09-28", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06745128", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Tirzepatide for Obesity and Meth Use Disorder", "sponsor": "University of Texas Southwestern Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06745128" }, { "observed": "2026-09-28", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06745128", "application": "", "field": "primary_completion_date", "previous": "2026-03-31", "current": "2026-02-12", "months": "-1", "significance": "0", "title": "Tirzepatide for Obesity and Meth Use Disorder", "sponsor": "University of Texas Southwestern Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06745128" }, { "observed": "2026-09-28", "kind": "enrollment", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06745128", "application": "", "field": "enrollment", "previous": "45", "current": "35", "months": "", "significance": "0", "title": "Tirzepatide for Obesity and Meth Use Disorder", "sponsor": "University of Texas Southwestern Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06745128" }, { "observed": "2026-09-28", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06861439", "application": "", "field": "primary_completion_date", "previous": "2026-09-30", "current": "2026-10-30", "months": "1", "significance": "0", "title": "GLP-1s to Enhance Lasting Optimal Weight", "sponsor": "Wake Forest University Health Sciences", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06861439" }, { "observed": "2026-09-28", "kind": "new", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07843862", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study of HRS-4729 Injection in Participants With Type 2 Diabetes", "sponsor": "Fujian Shengdi Pharmaceutical Co., Ltd.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07843862" }, { "observed": "2026-09-28", "kind": "status", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07441252", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight", "sponsor": "Amgen", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07441252" }, { "observed": "2026-09-28", "kind": "completion_moved", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07441252", "application": "", "field": "primary_completion_date", "previous": "2027-09-29", "current": "2027-08-25", "months": "-1", "significance": "0", "title": "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight", "sponsor": "Amgen", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07441252" }, { "observed": "2026-09-28", "kind": "gone", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07837973", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss", "sponsor": "Alveus Therapeutics, Inc.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07837973" }, { "observed": "2026-09-25", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06738979", "application": "", "field": "primary_completion_date", "previous": "2026-07", "current": "2026-03-07", "months": "-4", "significance": "1", "title": "A Clinical Study Comparing Semaglutide Injection and Wegovy\u00ae for Weight Management in Obese Subjects", "sponsor": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06738979" }, { "observed": "2026-09-25", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07254715", "application": "", "field": "primary_completion_date", "previous": "2026-04", "current": "2026-07-30", "months": "3", "significance": "1", "title": "Effect of Itopride on Semaglutide Gastroparesis", "sponsor": "Ain Shams University", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07254715" }, { "observed": "2026-09-25", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06738979", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "A Clinical Study Comparing Semaglutide Injection and Wegovy\u00ae for Weight Management in Obese Subjects", "sponsor": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06738979" }, { "observed": "2026-09-25", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07254715", "application": "", "field": "status", "previous": "RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Effect of Itopride on Semaglutide Gastroparesis", "sponsor": "Ain Shams University", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07254715" }, { "observed": "2026-09-24", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07837973", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss", "sponsor": "Alveus Therapeutics, Inc.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07837973" }, { "observed": "2026-09-23", "kind": "completion_moved", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07718126", "application": "", "field": "primary_completion_date", "previous": "2028-08-31", "current": "2029-02-28", "months": "6", "significance": "1", "title": "Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)", "sponsor": "West China Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07718126" }, { "observed": "2026-09-23", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07836140", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.", "sponsor": "Second Affiliated Hospital of Soochow University", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07836140" }, { "observed": "2026-09-23", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07734870", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Tirzepatide for Treatment of CCCA", "sponsor": "Johns Hopkins University", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07734870" }, { "observed": "2026-09-23", "kind": "status", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07718126", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)", "sponsor": "West China Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07718126" }, { "observed": "2026-09-23", "kind": "field_changed", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07718126", "application": "", "field": "phase", "previous": "P2/P3", "current": "P4", "months": "", "significance": "0", "title": "Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)", "sponsor": "West China Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07718126" }, { "observed": "2026-09-23", "kind": "new", "source": "trials", "drug": "ecnoglutide", "nct_id": "NCT07836270", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07836270" }, { "observed": "2026-09-22", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07834398", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes", "sponsor": "Zagazig University", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07834398" }, { "observed": "2026-09-22", "kind": "status", "source": "trials", "drug": "orforglipron", "nct_id": "NCT07794579", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07794579" }, { "observed": "2026-09-22", "kind": "status", "source": "trials", "drug": "mazdutide", "nct_id": "NCT06862908", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06862908" }, { "observed": "2026-09-21", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06173778", "application": "", "field": "primary_completion_date", "previous": "2026-07-01", "current": "2028-05-25", "months": "22", "significance": "1", "title": "Semaglutide for Post-Smoking Cessation Weight Management", "sponsor": "The University of Texas Health Science Center, Houston", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06173778" }, { "observed": "2026-09-21", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06050577", "application": "", "field": "primary_completion_date", "previous": "2026-01-15", "current": "2027-01-15", "months": "12", "significance": "1", "title": "The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial", "sponsor": "Odense University Hospital", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06050577" }, { "observed": "2026-09-21", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06864026", "application": "", "field": "primary_completion_date", "previous": "2027-11", "current": "2027-08", "months": "-3", "significance": "1", "title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "sponsor": "Eli Lilly and Company", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06864026" }, { "observed": "2026-09-21", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07832084", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s", "sponsor": "Jing Luo", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07832084" }, { "observed": "2026-09-21", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06864026", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "sponsor": "Eli Lilly and Company", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06864026" }, { "observed": "2026-09-21", "kind": "completion_moved", "source": "trials", "drug": "liraglutide", "nct_id": "NCT07225829", "application": "", "field": "primary_completion_date", "previous": "2026-08-28", "current": "2026-08-31", "months": "0", "significance": "0", "title": "A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis", "sponsor": "4Moving Biotech", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07225829" }, { "observed": "2026-09-21", "kind": "status", "source": "trials", "drug": "efinopegdutide", "nct_id": "NCT06465186", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)", "sponsor": "Merck Sharp & Dohme LLC", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06465186" }, { "observed": "2026-09-21", "kind": "completion_moved", "source": "trials", "drug": "efinopegdutide", "nct_id": "NCT06465186", "application": "", "field": "primary_completion_date", "previous": "2026-08-06", "current": "2026-08-03", "months": "0", "significance": "0", "title": "A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)", "sponsor": "Merck Sharp & Dohme LLC", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06465186" }, { "observed": "2026-09-21", "kind": "enrollment", "source": "trials", "drug": "efinopegdutide", "nct_id": "NCT06465186", "application": "", "field": "enrollment", "previous": "80", "current": "85", "months": "", "significance": "0", "title": "A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)", "sponsor": "Merck Sharp & Dohme LLC", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06465186" }, { "observed": "2026-09-21", "kind": "new", "source": "trials", "drug": "olatorepatide", "nct_id": "NCT07830329", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity", "sponsor": "Regeneron Pharmaceuticals", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07830329" }, { "observed": "2026-09-18", "kind": "new", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07829198", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial", "sponsor": "Universidade do Porto", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07829198" }, { "observed": "2026-09-18", "kind": "status", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07225686", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07225686" }, { "observed": "2026-09-18", "kind": "completion_moved", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07225686", "application": "", "field": "primary_completion_date", "previous": "2027-09-29", "current": "2027-09-03", "months": "0", "significance": "0", "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07225686" }, { "observed": "2026-09-17", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07220629", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)", "sponsor": "Rezera (formerly NodThera Limited)", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07220629" }, { "observed": "2026-09-17", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT05254314", "application": "", "field": "primary_completion_date", "previous": "2026-09", "current": "2026-09-30", "months": "0", "significance": "0", "title": "Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)", "sponsor": "Vanderbilt University Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT05254314" }, { "observed": "2026-09-17", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07777575", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide", "sponsor": "Technical University of Munich", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07777575" }, { "observed": "2026-09-17", "kind": "new", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07825857", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder", "sponsor": "University of Texas Southwestern Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07825857" }, { "observed": "2026-09-17", "kind": "new", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07824895", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Mazdutide for Weight Management and Gout in Adults With Obesity", "sponsor": "Hongwei Jiang", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07824895" }, { "observed": "2026-09-16", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06913023", "application": "", "field": "primary_completion_date", "previous": "2027-11-30", "current": "2029-06-30", "months": "19", "significance": "2", "title": "Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus", "sponsor": "University Health Network, Toronto", "phase": "P2/P3", "record_url": "https://clinicaltrials.gov/study/NCT06913023" }, { "observed": "2026-09-16", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06913023", "application": "", "field": "enrollment", "previous": "74", "current": "37", "months": "", "significance": "1", "title": "Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus", "sponsor": "University Health Network, Toronto", "phase": "P2/P3", "record_url": "https://clinicaltrials.gov/study/NCT06913023" }, { "observed": "2026-09-16", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07639021", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity", "sponsor": "Novo Nordisk A/S", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07639021" }, { "observed": "2026-09-16", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07639021", "application": "", "field": "primary_completion_date", "previous": "2027-07-12", "current": "2027-06-14", "months": "-1", "significance": "0", "title": "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity", "sponsor": "Novo Nordisk A/S", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07639021" }, { "observed": "2026-09-16", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07639021", "application": "", "field": "enrollment", "previous": "230", "current": "233", "months": "", "significance": "0", "title": "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity", "sponsor": "Novo Nordisk A/S", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07639021" }, { "observed": "2026-09-15", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT05569772", "application": "", "field": "primary_completion_date", "previous": "2029-06", "current": "2030-03", "months": "9", "significance": "2", "title": "Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes", "sponsor": "Universitaire Ziekenhuizen KU Leuven", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT05569772" }, { "observed": "2026-09-15", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07820111", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial", "sponsor": "Zagazig University", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07820111" }, { "observed": "2026-09-15", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07820358", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer", "sponsor": "The Methodist Hospital Research Institute", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07820358" }, { "observed": "2026-09-14", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06897475", "application": "", "field": "primary_completion_date", "previous": "2026-12", "current": "2027-05", "months": "5", "significance": "1", "title": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide", "sponsor": "Eli Lilly and Company", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06897475" }, { "observed": "2026-09-14", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07511543", "application": "", "field": "primary_completion_date", "previous": "2031-09-30", "current": "2028-10-31", "months": "-35", "significance": "1", "title": "Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy", "sponsor": "Population Health Research Institute", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07511543" }, { "observed": "2026-09-14", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06908694", "application": "", "field": "primary_completion_date", "previous": "2026-07-31", "current": "2027-10-31", "months": "15", "significance": "1", "title": "Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy", "sponsor": "Hamilton Health Sciences Corporation", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06908694" }, { "observed": "2026-09-14", "kind": "completion_moved", "source": "trials", "drug": "orforglipron", "nct_id": "NCT06649045", "application": "", "field": "primary_completion_date", "previous": "2026-11", "current": "2026-07-21", "months": "-4", "significance": "1", "title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06649045" }, { "observed": "2026-09-14", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07653477", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin \u00b1 Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)", "sponsor": "The United Bio-Technology (Hengqin) Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07653477" }, { "observed": "2026-09-14", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07817251", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema", "sponsor": "Novo Nordisk A/S", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07817251" }, { "observed": "2026-09-14", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06897475", "application": "", "field": "enrollment", "previous": "240", "current": "200", "months": "", "significance": "0", "title": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide", "sponsor": "Eli Lilly and Company", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06897475" }, { "observed": "2026-09-14", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07511543", "application": "", "field": "enrollment", "previous": "826", "current": "100", "months": "", "significance": "0", "title": "Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy", "sponsor": "Population Health Research Institute", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07511543" }, { "observed": "2026-09-14", "kind": "field_changed", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07511543", "application": "", "field": "phase", "previous": "P3", "current": "P2", "months": "", "significance": "0", "title": "Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy", "sponsor": "Population Health Research Institute", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07511543" }, { "observed": "2026-09-14", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07819227", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide", "sponsor": "University Medical Center Groningen", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07819227" }, { "observed": "2026-09-14", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06908694", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy", "sponsor": "Hamilton Health Sciences Corporation", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06908694" }, { "observed": "2026-09-14", "kind": "new", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07817875", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07817875" }, { "observed": "2026-09-14", "kind": "status", "source": "trials", "drug": "orforglipron", "nct_id": "NCT06649045", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06649045" }, { "observed": "2026-09-14", "kind": "enrollment", "source": "trials", "drug": "orforglipron", "nct_id": "NCT06649045", "application": "", "field": "enrollment", "previous": "600", "current": "712", "months": "", "significance": "0", "title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06649045" }, { "observed": "2026-09-11", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT05536804", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "sponsor": "Eli Lilly and Company", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT05536804" }, { "observed": "2026-09-11", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT05536804", "application": "", "field": "primary_completion_date", "previous": "2026-09", "current": "2026-07-06", "months": "-2", "significance": "0", "title": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "sponsor": "Eli Lilly and Company", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT05536804" }, { "observed": "2026-09-11", "kind": "enrollment", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT05536804", "application": "", "field": "enrollment", "previous": "140", "current": "134", "months": "", "significance": "0", "title": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "sponsor": "Eli Lilly and Company", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT05536804" }, { "observed": "2026-09-10", "kind": "new", "source": "approvals", "drug": "semaglutide", "nct_id": "", "application": "NDA209637", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "NOVO", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637" }, { "observed": "2026-09-10", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06691243", "application": "", "field": "primary_completion_date", "previous": "2026-07", "current": "2027-01", "months": "6", "significance": "1", "title": "Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV", "sponsor": "University of Maryland, Baltimore", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06691243" }, { "observed": "2026-09-10", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06691243", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV", "sponsor": "University of Maryland, Baltimore", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06691243" }, { "observed": "2026-09-10", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06797869", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy", "sponsor": "Novo Nordisk A/S", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06797869" }, { "observed": "2026-09-10", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06797869", "application": "", "field": "primary_completion_date", "previous": "2026-08-21", "current": "2026-06-26", "months": "-2", "significance": "0", "title": "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy", "sponsor": "Novo Nordisk A/S", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06797869" }, { "observed": "2026-09-10", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07812597", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)", "sponsor": "Beijing QL Biopharmaceutical Co.,Ltd", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07812597" }, { "observed": "2026-09-09", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07282613", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes", "sponsor": "Novo Nordisk A/S", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07282613" }, { "observed": "2026-09-09", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT06965413", "application": "", "field": "primary_completion_date", "previous": "2026-08-22", "current": "2026-09-03", "months": "1", "significance": "0", "title": "A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity", "sponsor": "Hoffmann-La Roche", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06965413" }, { "observed": "2026-09-09", "kind": "status", "source": "trials", "drug": "petrelintide", "nct_id": "NCT06926842", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)", "sponsor": "Zealand Pharma", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06926842" }, { "observed": "2026-09-08", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07059377", "application": "", "field": "primary_completion_date", "previous": "2026-07", "current": "2026-12", "months": "5", "significance": "1", "title": "Semaglutide for Smoking Cessation in Patients With Diabetes", "sponsor": "Ottawa Heart Institute Research Corporation", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07059377" }, { "observed": "2026-09-04", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06851962", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.", "sponsor": "Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06851962" }, { "observed": "2026-09-04", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06851962", "application": "", "field": "enrollment", "previous": "504", "current": "92", "months": "", "significance": "0", "title": "Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.", "sponsor": "Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06851962" }, { "observed": "2026-09-04", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07446998", "application": "", "field": "status", "previous": "RECRUITING", "current": "ACTIVE_NOT_RECRUITING", "months": "", "significance": "0", "title": "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss", "sponsor": "Veru Inc.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07446998" }, { "observed": "2026-09-04", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07446998", "application": "", "field": "enrollment", "previous": "200", "current": "239", "months": "", "significance": "0", "title": "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss", "sponsor": "Veru Inc.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07446998" }, { "observed": "2026-09-04", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07745504", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight", "sponsor": "Novo Nordisk A/S", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07745504" }, { "observed": "2026-09-03", "kind": "field_changed", "source": "labels", "drug": "tirzepatide", "nct_id": "", "application": "NDA215866", "field": "conditions", "previous": "type-2-diabetes", "current": "cardiovascular-disease; type-2-diabetes", "months": "", "significance": "2", "title": "", "sponsor": "", "phase": "", "record_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0" }, { "observed": "2026-09-03", "kind": "new", "source": "approvals", "drug": "tirzepatide", "nct_id": "", "application": "NDA215866", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "ELI LILLY AND CO", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866" }, { "observed": "2026-09-03", "kind": "new", "source": "approvals", "drug": "tirzepatide", "nct_id": "", "application": "NDA217806", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "ELI LILLY AND CO", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806" }, { "observed": "2026-09-03", "kind": "field_changed", "source": "labels", "drug": "tirzepatide", "nct_id": "", "application": "NDA215866", "field": "indications", "previous": "MOUNJARO \u00ae is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO \u00ae is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )", "current": "MOUNJARO \u00ae is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. MOUNJARO \u00ae is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )", "months": "", "significance": "1", "title": "", "sponsor": "", "phase": "", "record_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0" }, { "observed": "2026-09-03", "kind": "field_changed", "source": "labels", "drug": "tirzepatide", "nct_id": "", "application": "NDA217806", "field": "effective", "previous": "2026-04-22", "current": "2026-08-28", "months": "", "significance": "0", "title": "", "sponsor": "", "phase": "", "record_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b" }, { "observed": "2026-09-03", "kind": "field_changed", "source": "labels", "drug": "tirzepatide", "nct_id": "", "application": "NDA215866", "field": "effective", "previous": "2026-07-29", "current": "2026-08-27", "months": "", "significance": "0", "title": "", "sponsor": "", "phase": "", "record_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0" }, { "observed": "2026-09-03", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06803888", "application": "", "field": "enrollment", "previous": "125", "current": "140", "months": "", "significance": "0", "title": "Bariatric Surgery vs. Semaglutide vs. Tirzepatide", "sponsor": "Ali Aminian", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06803888" }, { "observed": "2026-09-03", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07801820", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus", "sponsor": "Shanghai Minwei Biotechnology Co., Ltd", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07801820" }, { "observed": "2026-09-02", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06762314", "application": "", "field": "primary_completion_date", "previous": "2027-09-20", "current": "2026-01-20", "months": "-20", "significance": "1", "title": "Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes", "sponsor": "Mostafa Bahaa", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06762314" }, { "observed": "2026-09-02", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06762314", "application": "", "field": "status", "previous": "RECRUITING", "current": "COMPLETED", "months": "", "significance": "0", "title": "Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes", "sponsor": "Mostafa Bahaa", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06762314" }, { "observed": "2026-09-02", "kind": "enrollment", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06762314", "application": "", "field": "enrollment", "previous": "105", "current": "114", "months": "", "significance": "0", "title": "Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes", "sponsor": "Mostafa Bahaa", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06762314" }, { "observed": "2026-09-02", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06557811", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "UNKNOWN", "months": "", "significance": "0", "title": "Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction", "sponsor": "University of Sao Paulo General Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06557811" }, { "observed": "2026-09-01", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07797036", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes", "sponsor": "University of Massachusetts, Worcester", "phase": "P2/P3", "record_url": "https://clinicaltrials.gov/study/NCT07797036" }, { "observed": "2026-09-01", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06299098", "application": "", "field": "primary_completion_date", "previous": "2026-05-06", "current": "2026-06-16", "months": "1", "significance": "0", "title": "A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation", "sponsor": "Regeneron Pharmaceuticals", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06299098" }, { "observed": "2026-09-01", "kind": "new", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07796477", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin", "sponsor": "CSPC Ouyi Pharmaceutical Co., Ltd.", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07796477" }, { "observed": "2026-08-31", "kind": "new", "source": "trials", "drug": "orforglipron", "nct_id": "NCT07794579", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07794579" }, { "observed": "2026-08-31", "kind": "new", "source": "trials", "drug": "pemvidutide", "nct_id": "NCT07795164", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH", "sponsor": "Altimmune, Inc.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07795164" }, { "observed": "2026-08-31", "kind": "status", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06934655", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial", "sponsor": "Children's Hospital Los Angeles", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06934655" }, { "observed": "2026-08-31", "kind": "status", "source": "trials", "drug": "liraglutide", "nct_id": "NCT06559722", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "UNKNOWN", "months": "", "significance": "0", "title": "A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes", "sponsor": "Tonghua Dongbao Pharmaceutical Co.,Ltd", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06559722" }, { "observed": "2026-08-31", "kind": "status", "source": "trials", "drug": "mazdutide", "nct_id": "NCT06164873", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "UNKNOWN", "months": "", "significance": "0", "title": "A Study of IBI362 9 mg in Chinese Adults With Obesity", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT06164873" }, { "observed": "2026-08-31", "kind": "status", "source": "trials", "drug": "ecnoglutide", "nct_id": "NCT07734311", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07734311" }, { "observed": "2026-08-28", "kind": "field_changed", "source": "shortages", "drug": "liraglutide", "nct_id": "", "application": "", "field": "reason", "previous": "Estimated recovery: July 2026", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/drugshortages/" }, { "observed": "2026-08-28", "kind": "completion_moved", "source": "trials", "drug": "semaglutide", "nct_id": "NCT06548490", "application": "", "field": "primary_completion_date", "previous": "2027-04", "current": "2027-04-30", "months": "0", "significance": "0", "title": "GLP-1R Agonist Treatment for Opioid Use Disorder", "sponsor": "Milton S. Hershey Medical Center", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06548490" }, { "observed": "2026-08-28", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07191873", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Tirzepatide in Idiopathic Intracranial Hypertension Trial", "sponsor": "Duke University", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07191873" }, { "observed": "2026-08-28", "kind": "completion_moved", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07657676", "application": "", "field": "primary_completion_date", "previous": "2027-10-31", "current": "2027-12-31", "months": "2", "significance": "0", "title": "Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity", "sponsor": "China National Center for Cardiovascular Diseases", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07657676" }, { "observed": "2026-08-27", "kind": "new", "source": "approvals", "drug": "tirzepatide", "nct_id": "", "application": "NDA215866", "field": "", "previous": "", "current": "", "months": "", "significance": "2", "title": "", "sponsor": "ELI LILLY AND CO", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866" }, { "observed": "2026-08-27", "kind": "new", "source": "approvals", "drug": "tirzepatide", "nct_id": "", "application": "NDA215866", "field": "", "previous": "", "current": "", "months": "", "significance": "2", "title": "", "sponsor": "ELI LILLY AND CO", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866" }, { "observed": "2026-08-27", "kind": "new", "source": "approvals", "drug": "semaglutide", "nct_id": "", "application": "NDA209637", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "", "sponsor": "NOVO", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637" }, { "observed": "2026-08-27", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07154719", "application": "", "field": "status", "previous": "ACTIVE_NOT_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "GLP-1R Actions on Muscle and the Skeleton", "sponsor": "Pennington Biomedical Research Center", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07154719" }, { "observed": "2026-08-27", "kind": "new", "source": "trials", "drug": "orforglipron", "nct_id": "NCT07790861", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems", "sponsor": "Eli Lilly and Company", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07790861" }, { "observed": "2026-08-26", "kind": "new", "source": "approvals", "drug": "tirzepatide", "nct_id": "", "application": "NDA217806", "field": "", "previous": "", "current": "", "months": "", "significance": "2", "title": "", "sponsor": "ELI LILLY AND CO", "phase": "", "record_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806" }, { "observed": "2026-08-26", "kind": "completion_moved", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07349641", "application": "", "field": "primary_completion_date", "previous": "2028-12-31", "current": "2029-10-31", "months": "10", "significance": "1", "title": "A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer", "sponsor": "National Cancer Institute (NCI)", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07349641" }, { "observed": "2026-08-25", "kind": "new", "source": "trials", "drug": "semaglutide", "nct_id": "NCT07783854", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity", "sponsor": "Union Hospital, Tongji Medical College, Huazhong University of Science and Technology", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07783854" }, { "observed": "2026-08-24", "kind": "status", "source": "trials", "drug": "tirzepatide", "nct_id": "NCT07554638", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Incretin Therapies in Obesity-related HFpEF", "sponsor": "Columbia University", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07554638" }, { "observed": "2026-08-24", "kind": "new", "source": "trials", "drug": "mazdutide", "nct_id": "NCT07781150", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer", "sponsor": "Tongji Hospital", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07781150" }, { "observed": "2026-08-24", "kind": "status", "source": "trials", "drug": "maridebart cafraglutide", "nct_id": "NCT07684144", "application": "", "field": "status", "previous": "NOT_YET_RECRUITING", "current": "RECRUITING", "months": "", "significance": "0", "title": "Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)", "sponsor": "Amgen", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07684144" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT05413369", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT05413369" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02058160", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02058160" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02058147", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02058147" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01147250", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01147250" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02752412", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02752412" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00712673", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00712673" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01768559", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01768559" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03798054", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT03798054" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00713830", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00713830" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02752828", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02752828" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "aleniglipron", "nct_id": "NCT07654374", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07654374" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "aleniglipron", "nct_id": "NCT07654361", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT07654361" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT00839527", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00839527" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT00976391", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00976391" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT01098539", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01098539" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT00838916", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00838916" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT02229227", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02229227" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT00838903", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "1", "title": "Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00838903" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02049034", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes", "sponsor": "University of Surrey", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02049034" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT07173712", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes", "sponsor": "Yanbing Li", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07173712" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01940965", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01940965" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03798080", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT03798080" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01798706", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01798706" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02749890", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02749890" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03434119", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT03434119" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT07117240", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes", "sponsor": "Medical University of Warsaw", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07117240" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01910194", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying", "sponsor": "Profil Institut f\u00fcr Stoffwechselforschung GmbH", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT01910194" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03767543", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua\u2122) in Patients With Type 2 Diabetes Mellitus (T2DM)", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT03767543" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT05804513", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "The Effect of Lixisenatide on the Effect of Pituitary Hormones", "sponsor": "University of Tartu", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT05804513" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00715624", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00715624" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03439943", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease", "sponsor": "University Hospital, Toulouse", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT03439943" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00905255", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00905255" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03819790", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians", "sponsor": "LMC Diabetes & Endocrinology Ltd.", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT03819790" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02767596", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog", "sponsor": "Laniado Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02767596" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01960179", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01960179" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02941367", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan", "sponsor": "Sanofi", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02941367" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00763815", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00763815" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02020629", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Study on Lixisenatide and Counterregulation to Hypoglycemia", "sponsor": "Lund University", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02020629" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00688701", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00688701" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03881995", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Effects of Insulin Glargine and Lixisenatide on the Brain", "sponsor": "University Hospital Tuebingen", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT03881995" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03529123", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT03529123" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01169779", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01169779" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00976937", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00975286", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00975286" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT05114590", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus", "sponsor": "Sanofi", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT05114590" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT06671587", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "iGlarLixi CGM Study in Chinese T2D Individuals After OADs", "sponsor": "Sanofi", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06671587" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00299871", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus", "sponsor": "Sanofi", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT00299871" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01476475", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients", "sponsor": "Sanofi", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT01476475" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT07307235", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents", "sponsor": "Shanghai Zhongshan Hospital", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT07307235" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00866658", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00866658" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02168491", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin", "sponsor": "Medical University of Vienna", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02168491" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02274740", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients", "sponsor": "Sanofi", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT02274740" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT00763451", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00763451" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02200991", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine", "sponsor": "Sanofi", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02200991" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT03130426", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi", "sponsor": "Population Health Research Institute", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT03130426" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT06716424", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus", "sponsor": "Sanofi", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT06716424" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT02276196", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Effect of LIXIsenatide on the Renal System", "sponsor": "Amsterdam UMC, location VUmc", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02276196" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01632163", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01632163" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "lixisenatide", "nct_id": "NCT01517412", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin", "sponsor": "Sanofi", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01517412" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "aleniglipron", "nct_id": "NCT07400588", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Aleniglipron Phase 2 in Type 2 Diabetes Mellitus", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07400588" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "aleniglipron", "nct_id": "NCT07169942", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Aleniglipron Phase 2 Body Composition Study", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07169942" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "aleniglipron", "nct_id": "NCT06693843", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06693843" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "aleniglipron", "nct_id": "NCT06703021", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT06703021" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "olatorepatide", "nct_id": "NCT07685808", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes", "sponsor": "Regeneron Pharmaceuticals", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07685808" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "olatorepatide", "nct_id": "NCT07431086", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US", "sponsor": "Regeneron Pharmaceuticals", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT07431086" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT02284009", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT02284009" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT01098461", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Dose Ranging Study of Albiglutide in Japanese Subjects", "sponsor": "GlaxoSmithKline", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT01098461" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT03015519", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT03015519" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT00849017", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Safety and Efficacy Study of Albiglutide in Type 2 Diabetes", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00849017" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT02465515", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02465515" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT01777282", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT01777282" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT01475734", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes", "sponsor": "GlaxoSmithKline", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT01475734" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT00849056", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Safety and Efficacy of Albiglutide in Type 2 Diabetes", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT00849056" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT00354536", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT00354536" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT02750930", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects", "sponsor": "GlaxoSmithKline", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02750930" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT01357889", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Pharmacokinetics/Pharmacodynamics of Albiglutide", "sponsor": "GlaxoSmithKline", "phase": "P2", "record_url": "https://clinicaltrials.gov/study/NCT01357889" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT02683746", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02683746" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT02229240", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus", "sponsor": "GlaxoSmithKline", "phase": "P3", "record_url": "https://clinicaltrials.gov/study/NCT02229240" }, { "observed": "2026-08-21", "kind": "new", "source": "", "drug": "albiglutide", "nct_id": "NCT02496221", "application": "", "field": "", "previous": "", "current": "", "months": "", "significance": "0", "title": "A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects", "sponsor": "GlaxoSmithKline", "phase": "P4", "record_url": "https://clinicaltrials.gov/study/NCT02496221" } ] }